Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Loading...
Embargo End Date
ICR Authors
Authors
Monk, BJ
Smith, G
Lima, J
Long, GH
Alam, N
Nakamura, H
Meulendijks, D
Ghiorghiu, D
Banerjee, S
Smith, G
Lima, J
Long, GH
Alam, N
Nakamura, H
Meulendijks, D
Ghiorghiu, D
Banerjee, S
Document Type
Journal Article
Date
2022-02-01
Date Accepted
2021-12-04
Abstract
OBJECTIVES: To characterize clinical outcomes of women with advanced/recurrent endometrial cancer (AEC) in routine practice using electronic health records from a real-world database. METHODS: Adult women diagnosed with AEC (stage III/IV, or early stage with locoregional/distant recurrence) between January 1, 2013 and September 30, 2020, inclusive, were eligible provided they received platinum-based chemotherapy at any time following diagnosis and had ≥2 clinical visits. Follow-up was from initiation of systemic treatment after advanced diagnosis (index) until March 30, 2021, last available follow-up, or death, whichever occurred first. Outcomes, by histological subtype, included Kaplan-Meier estimates of overall survival (OS) and time to first subsequent therapy or death (TFST). RESULTS: Of the 2202 women with AEC, most were treated in a community setting (82.7%) and presented with stage III/IV disease at initial diagnosis (74.0%). The proportion with endometrioid carcinoma, uterine serous carcinoma (USC), and other AEC subtypes was 59.8%, 25.0%, and 15.2%, respectively. The most common first systemic treatment following advanced/recurrent diagnosis was platinum-based combination chemotherapy (82.0%). Median OS (95% CI) from initiation of first systemic treatment was shorter with USC (31.3 [27.7-34.3] months) and other AECs (29.4 [21.4-43.9] months) versus endometrioid carcinoma (70.8 [60.5-83.2] months). Similar results were observed for TFST. Black/African American women had worse OS and TFST than white women. CONCLUSIONS: Women with AEC had poor survival outcomes, demonstrating the requirement for more effective therapies. To our knowledge, this is the most comprehensive evaluation of contemporary treatment of AEC delivered in a community setting to date.
Citation
Gynecologic oncology, 2022, 164 (2), pp. 325 - 332
Source Title
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
ISSN
0090-8258
eISSN
1095-6859